National and Kapodistrian University of Athens
Αξιολόγηση με ΗLA της ανοσολογικής παρέμβασης σε ασθενείς με κακοήθη αιματολογικά ή δερματολογικά νοσήματα
Abstract
dc:descriptionInterferon is approved for adjuvant treatment of patients with stage IIB/III melanoma since 1996. Acceptance has been limited due to toxicity and lack of survival benefit. The identification of predictive markers that would permit selection of patients would be beneficial. Specific HLA class I and II antigens have previously shown an association with response to therapy or overall survival of patients with metastatic melanoma. Experimental design: 284 melanoma patients and 246 healthy controls were molecularly typed for HLA class I and II. Specific allele frequencies were compared between the healthy and patient populations, as well as presence or absence of these in relation to recurrence. Alleles related to autoimmune disease were also investigated. Results: No significant differences were found between the distributions of HLA genotype in the melanoma population compared with healthy controls. Correlations between non-recurrence and the presence of HLA Cw*06 allele were noted (p-values 0.05). The median relapse-free survival of the Cw*06 positive cohort was 100.3 months versus 35.7 months in the Cw*06 negative cohort (p-value 0.020). The median overall survival for the Cw*06 positive cohort has not reached yet versus 76.53 months in the Cw*06 negative cohort (p-value 0.017). HLA-Cw*06 was present in 29.79% of patients in the autoimmunity group and 15.38% of patients in the non-autoimmunity group (p=0.049). Conclusion: HLA genotype does not influence the likelihood of a favourable outcome of interferon adjuvant therapy with the exception of HLA-Cw*06, an allele correlated with psoriasis . HLA-Cw*06 positive patients have a better relapse free and overall survival
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sinifakoulis, Haris
- Συνειφακούλης, Θεοχάρης
Subjects
dc:subject × 17- Μελάνωμα
- Αυτοάνοσα νοσήματα
- Ιντερφερόνη, Επικουρική θεραπεία με
- Μελάνωμα υψηλού κινδύνου
- Μοριακή ανάλυση των HLA
- Melanoma
- HLA
- IFN-a2b
- HLA CW* 06
- Autoimmung diseases
- Adjuvant interferon treatment
- High risk melanoma
- Molecular analysis of HLA
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19918